As Christmas approaches, it’s time to think of enlightening books for the businesspeople on your gift-giving list. The timeless books highlighted here, with their lessons on tempering bold risks with caution and staying close to the customer, have become more relevant since their initial publication. This is a rip-roaring story with insights on human ingenuity, fatal arrogance, and corporate cupidity on each of its succinct 193 pages. Its two heroes are Chesley “Sully” Sullenberger, who safely landed his crippled Airbus A320 on the Hudson River in 2009, and Bernard Ziegler, the engineering czar at Airbus SE who made Sully’s miracle possible. Ziegler convinced Airbus to adopt his invention of “fly-by wire,” a revolutionary automatic flight-control system that has helped the world’s more than 300,000 airline pilots save thousands of lives. Airbus introduced fly-by-wire in 1983; it has since been adopted by Boeing and other aircraft makers. Ziegler, a former French Air Force fighter pilot who saw action in the Algerian war, knew that wise pilots acknowledge their fallibility. But others, stricken by hubris, recommit to a mistake rather than admit error and correct it. In telling the author his motive for making a plane as goof-proof as possible, Ziegler cites a widely applicable adage: “To err is human, but to persist is diabolical.” This award-winning book tells the story of marketer Dave Nichol’s role in building Loblaw Cos. from a sleepy Ontario supermarket chain into one of the world’s biggest grocery retailers. That transformation, starting in the early 1980s, was largely accomplished with the triumph of Nichol’s private label “President’s Choice” goods over pricier and sometimes inferior national brands, available exclusively at Loblaws and its sister chains No Frills, Fortinos, Provigo and others. Nichol constantly refreshed the line of PC products with new and often improbable items like Memories of Szechwan Peanut Sauce and gourmet Italian dog food, obliging Loblaw patrons to visit frequently for the next talked-about PC products. These were showcased in Nichol’s chatty and widely read “Insider’s Report” flyer. Kingston also opens windows to the often-secretive worlds of new-product development and the strategies by which food purveyors try to change consumer tastes. Nichol’s Loblaws was a precursor to personality driven enterprises led by Elon Musk and his ilk, where the chief product is the ethos created by the marketer. This acclaimed memoir tells two important stories, of IBM’s bet-the-company investment in the mainframe computers that would become ubiquitous at public and private institutions worldwide in the mid-20th century; and the difficult relationship between the author and his larger-than-life namesake father, founder of the modern IBM, whose punch-card tabulating machines had about 90 per cent of the U.S. market. Yet it was Watson Jr., CEO from 1956 to 1971, whose IBM would succeed where others failed in embracing a disruptive technology at the expense of a lucrative existing business destined for obsolesce. Watson Jr. succeeded with a “family” of progressively more powerful yet compatible mainframes, dubbed System/360, by which customers could easily trade up as their needs grew. The book offers a winsome model of visionary action that is disciplined by careful risk calculation. It also tells of the fights between father and son that the author describes as “savage, primal, and unstoppable.” The story is relevant in a contemporary Canadian economy where family feuds over succession have jeopardized some of the country’s largest enterprises. Meet the young men, some almost frightfully immature, who helped launch the Information Age in which we now live. This comprehensive history might also be the most entertaining saga of how computing devices became everyday appliances. The revolution started with the desktop PCs that scruffy tech entrepreneurs like Bill Gates and Steve Jobs kept tweaking until they became more powerful than the room-sized mainframe computers that had ruled computing since the 1960s. The book is an immersive experience in which the reader is a first-hand witness to the fierce debates among inventors over their competing operating systems and hardware designs. At times the geeks collaborated, at others they sabotaged each other, all the while outfoxing IBM and the other tech giants of their day. There’s a lesson here on the speed and daring of innovation in a wide-open field. Eventually the boys’ fledgling enterprises became today’s Microsoft, Apple and Oracle, bureaucratic near-monopolies with limited innovative prowess, just like the earlier giants they supplanted. Happy holidays, and happy reading!
‘Tis the season for Christmas movies, and one of the most-talked about of the season so far is Hot Frosty . The rom-com, which is available to stream with a Netflix subscription , tells the story of an especially sexy snowman, who comes to life and romances a lonely woman. So far, the film is generating some serious buzz, by the looks of social media. It seems that it's now even managed to garner the attention of Ryan Reynolds and his Aviator Gin brand, which spoofed the movie with an A+ ad. Never one to pass up an opportunity, Ryan Reynolds shared the yuletide advertisement to Instagram. In the video, the A-lister himself is put in the place of the snowman. While it seems to be set up like the situation from the 2024 movie release , this scenario merely sees the young lady simply wanting a decent cocktail. Check it out. A post shared by Ryan Reynolds (@vancityreynolds) A photo posted by on In the film, a well-placed scarf brings a snowman to life. Here, the woman simply uses to swipe the bottle of gin because, seriously, if you saw a full bottle of gin being held by a snowman, is there a reason you wouldn’t take it home? Well, apparently because mutilating a snowman hurts. I may never make a snowman again. Ryan Reynolds owns an ad agency, Maximum Effort, which produces commercials for many different companies, including his own business interests like Aviation Gin and Mint Mobile. Many of the ads Reynolds' company has done have cashed in on cultural moments. For instance, the company previously made a Pelaton ad , when And Just Like That... used the product in a way that generated press. The ads frequently go viral, because they are entertaining; and this snowman-centric bit is no exception. The battle of the celebrity booze is, if nothing else, quite entertaining for the rest of us. At this point, numerous celebrities have their own alcohol brand, or in the case of Tom Holland , non-alcoholic beer. They can be quite profitable for the stars, especially when they sell them and can make literally billions. ( George Clooney pocketed a lot of cash when he did just that.) Until then, they all get to have some fun using their celebrity to help promote the brand. Matthew McConaughey has been dropping equally hilarious ads for his tequila brand, frequently making parodies of his movies, sans pants. I'm interested in seeing what the shelf life of this ad ends up being. Of course, it will greatly depend on the commercial and possibly critical success of Hot Frosty . The beauty of the best Christmas movies is that if they become a hit, they can essentially live forever as fans return to them year after year. Of course, even if they’re initially successful, most holiday flicks don’t have that kind of staying power. CINEMABLEND NEWSLETTER Your Daily Blend of Entertainment News If Hot Frosty becomes a movie that people watch every holiday season then this could be an Aviation Gin ad we also see every holiday season. Otherwise, nobody will remember why this is even funny in a couple of years. Still, for this year, the ad is perfection. And it makes me want to pick up a bottle of the gin for a holiday G&T, which I suppose is the point.I’m a Celeb fans blast Dean McCullough as he makes ‘cheeky’ request to Danny Jones
Your Guide To FII Positions For Nov. 25 Trade - NDTV ProfitPolitics Trump Names Scott Bessent as Treasury Secretary in Cabinet Shakeup By mayukh - November 23, 2024 Donald Trump has nominated Scott Bessent, a seasoned Wall Street financier, to lead the US Treasury Department as part of his second-term cabinet. The announcement on Friday evening ends weeks of speculation surrounding the influential role , which oversees tax policy, international finance, sanctions, and public debt. Trump praised Bessent as a “foremost international investor and geopolitical strategist” and a strong supporter of the America First agenda. Known for his economic acumen, Bessent, 62, previously worked for George Soros before founding Key Square Capital Management. He has also been a vocal advocate for Trump’s tax and trade policies, particularly extending the tax cuts from Trump’s first term , which are set to expire next year. A Balancing Act on Policy Through Scott Bessent If confirmed by the Senate, Bessent faces immediate challenges, including a Congressional showdown to extend the 2017 tax cuts. Calling their expiration “the largest tax increase in US history,” Bessent has vowed to prioritize keeping the cuts intact. His stance on tariffs aligns with Trump’s protectionist agenda, viewing them as valuable negotiation tools rather than rigid policy. Despite concerns from traditional economic circles, Scott Bessent’s nomination signals continuity in Trump’s push for deregulation, lower taxes, and an expanded role for the US in cryptocurrency. If confirmed, Bessent would become the first Treasury Secretary to openly champion the crypto industry, signaling a potential pivot in US financial leadership. Hailing from South Carolina, Scott Bessent is deeply rooted in philanthropy and family values, sharing a home with his husband and two children. His pragmatic approach to trade and finance is seen as a moderating influence compared to more hardline contenders. As Bessent prepares to step into this pivotal role, he inherits the task of managing federal debt, a contentious issue for Republicans and financial markets alike, while championing Trump’s vision for economic leadership in a volatile global landscape. TAGS Scott Bessent Facebook Twitter Pinterest WhatsApp Linkedin ReddIt Email Telegram Previous article Daniel Jones Released by New York Giants After Emotional Farewell mayukh http://digitalmarketnews.com
Australia to Ban Teens from Tiktok, Instagram, X, Snapchat
Monsanto added six rebounds for the Roadrunners (6-5). Sky Wicks scored 20 points while shooting 8 for 12, including 4 for 7 from beyond the arc and added eight rebounds and three steals. Amir "Primo" Spears shot 5 of 10 from the field, including 1 for 5 from 3-point range, and went 5 for 6 from the line to finish with 16 points. Domonique Wilkins and Orlando Gooden each scored 19 points for Southwestern Adventist. Jason Garcia had 13 points, four assists and two steals. Monsanto led his team in scoring with 16 points in the first half to help put them up 61-24 at the break. UTSA extended its lead to 87-38 during the second half, fueled by a 13-3 scoring run. Wicks scored a team-high 10 points in the second half. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .
CARLSBAD, Calif. , Dec. 19, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved TRYNGOLZATM (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a rare, genetic form of severe hypertriglyceridemia (sHTG) that can lead to potentially life-threatening acute pancreatitis (AP). TRYNGOLZA is the first-ever FDA-approved treatment that significantly and substantially reduces triglyceride levels in adults with FCS and provides clinically meaningful reduction in AP events when used with an appropriate diet (≤20 grams of fat per day). TRYNGOLZA is self-administered via an auto-injector once monthly. Experience the full interactive Multichannel News Release here: https://www.multivu.com/ionis-pharmaceuticals/9295551-en-tryngolza-olezarsen-fda-approval "Today's FDA approval of TRYNGOLZA heralds the arrival of the first-ever FCS treatment in the U.S. – a transformational moment for patients and their families. For the first time, adults with FCS can now access a treatment that substantially reduces triglycerides and the risk of debilitating and potentially life-threatening acute pancreatitis," said Brett P. Monia , Ph.D., chief executive officer, Ionis. "We are proud of our long-standing partnership with the FCS community and are grateful to the patients, families and investigators who participated in our clinical studies, enabling Ionis to make this new treatment a reality. The FDA approval of TRYNGOLZA is also a pivotal moment for Ionis, representing our evolution into a fully integrated commercial-stage biotechnology company – a goal we set out to achieve five years ago. With our rich pipeline of potentially life-changing medicines, we expect TRYNGOLZA to be the first in a steady cadence of innovative medicines we will deliver independently to people living with serious diseases." The FDA approval was based on positive data from the global, multicenter, randomized, placebo-controlled, double-blind Phase 3 Balance clinical trial in adult patients with genetically identified FCS and fasting triglyceride levels ≥880 mg/dL. In the Balance study, TRYNGOLZA 80 mg demonstrated a statistically significant placebo-adjusted mean reduction in triglyceride levels of 42.5% from baseline to six months (p=0.0084). Reductions from baseline to 12 months were further improved, with TRYNGOLZA achieving a placebo-adjusted 57% mean reduction in triglycerides. TRYNGOLZA also demonstrated a substantial, clinically meaningful reduction in AP events over 12 months; one patient (5%) experienced one episode of AP in the TRYNGOLZA group compared with seven patients (30%) who experienced 11 total episodes of AP in the placebo group. TRYNGOLZA demonstrated a favorable safety profile. The most common adverse reactions (incidence >5% of TRYNGOLZA-treated patients and at a >3% higher frequency than placebo) were injection site reactions (19% and 9%, respectively), decreased platelet count (12% and 4%, respectively) and arthralgia (9% and 0%, respectively). Results from the Phase 3 Balance study were previously published in The New England Journal of Medicine (NEJM). "With no treatment options previously available, we were limited to relying only on extremely strict diet and lifestyle changes as the sole preventative treatment option," said Alan Brown , M.D., FNLA, FACC, FAHA, clinical professor of medicine, Rosalind Franklin University of Medicine and Science ; Balance trial investigator. "The FDA approval of TRYNGOLZA is an important moment for people living with FCS, their families and physicians who now, for the first time, have a treatment that significantly lowers triglycerides and decreases the risk of potentially life-threatening acute pancreatitis events, as an adjunct to a low-fat diet. I am excited to have a medicine I can prescribe to my patients that has been shown to change the course of their disease." FCS is a rare, genetic, potentially life-threatening form of sHTG that prevents the body from breaking down fats and severely impairs the body's ability to remove triglycerides from the bloodstream due to an impaired function of the enzyme lipoprotein lipase (LPL). While healthy levels for adults are below 150 mg/dL, people with FCS often have triglyceride levels of more than 880 mg/dL and often have a history of pancreatitis. Those living with FCS have a high risk of potentially fatal AP, which is a painful inflammation of the pancreas, and chronic health issues such as fatigue and severe, recurrent abdominal pain. People living with FCS can also experience psychological and financial stress, which can significantly impact their quality of life. In the U.S., FCS is estimated to impact up to approximately 3,000 people, the vast majority of whom remain undiagnosed. "As a rare and difficult to diagnose disease, FCS has a profound impact on the lives of patients and families. Many people living with FCS have experienced severe pain their whole lives – sometimes so intense they require lengthy hospitalization stays – and struggle through life with daily fatigue, nausea, brain fog and stomach pain," said Lindsey Sutton Bryan , co-founder and co-president, FCS Foundation. "Until now, our treatment options have been limited, relying on diet alone to try to manage triglyceride levels and keep acute pancreatitis attacks at bay. For the first time, adults with FCS have seen their hope for a treatment become a reality." TRYNGOLZA will be available in the U.S. before year end. Ionis is committed to helping people access the medicines they are prescribed and will offer a suite of services designed to meet the unique needs of the FCS community through Ionis Every StepTM. As part of Ionis Every Step , patients and healthcare providers will have access to services throughout the treatment journey provided by dedicated Patient Education Managers and Ionis Every Step Case Managers, including insurance and affordability support, as well as services and resources, such as disease and nutrition education. Visit TRYNGOLZA.com for more information. TRYNGOLZA was reviewed by the FDA under Priority Review and had previously been granted Fast Track designation for the treatment of FCS, Orphan Drug designation and Breakthrough Therapy designation. Olezarsen is undergoing review in the European Union and regulatory filings in other countries are planned. Olezarsen is currently being evaluated in three Phase 3 clinical trials – CORE, CORE2 and ESSENCE – for the treatment of sHTG. Olezarsen has not been reviewed or approved for the treatment of sHTG by regulatory authorities. Webcast Ionis will hold a webcast today at 6:45pm ET to discuss the FDA approval. Interested parties may access the webcast here . A webcast replay will be available for a limited time. About TRYNGOLZATM (olezarsen) TRYNGOLZATM (olezarsen) was approved by the U.S. Food and Drug Administration as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). TRYNGOLZA is an RNA-targeted medicine designed to lower the body's production of apoC-III, a protein produced in the liver that is a key regulator of triglyceride metabolism. It is the only treatment currently indicated in the U.S. for FCS, a potentially life-threatening disease. For more information about TRYNGOLZA, visit TRYNGOLZA.com . IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS TRYNGOLZA is contraindicated in patients with a history of serious hypersensitivity to TRYNGOLZA or any of the excipients in TRYNGOLZA. Hypersensitivity reactions requiring medical treatment have occurred. WARNINGS AND PRECAUTIONS Hypersensitivity Reactions Hypersensitivity reactions (including symptoms of bronchospasm, diffuse erythema, facial swelling, urticaria, chills and myalgias) have been reported in patients treated with TRYNGOLZA. Advise patients on the signs and symptoms of hypersensitivity reactions and instruct patients to promptly seek medical attention and discontinue use of TRYNGOLZA if hypersensitivity reactions occur. ADVERSE REACTIONS The most common adverse reactions (incidence >5% of TRYNGOLZA-treated patients and >3% higher frequency than placebo) were injection site reactions, decreased platelet count and arthralgia. Please see full Prescribing Information for TRYNGOLZA. About Familial Chylomicronemia Syndrome (FCS) FCS is a rare, genetic disease characterized by extremely elevated triglyceride levels. It is caused by impaired function of the enzyme lipoprotein lipase (LPL). Because of limited LPL production or function, people with FCS cannot effectively break down chylomicrons, lipoprotein particles that are 90% triglycerides. FCS is estimated to impact up to approximately 3,000 people in the U.S. People living with FCS are at high risk of acute pancreatitis (AP) in addition to other chronic health issues such as fatigue and severe, recurrent abdominal pain. People living with FCS are sometimes unable to work, adding to the burden of disease. About the Balance Study Balance is a global, multicenter, randomized, double-blind, placebo-controlled Phase 3 study evaluating the efficacy and safety of olezarsen in patients with FCS at six and 12 months. The primary endpoint was the percent change from baseline in fasting triglyceride levels at six months compared to placebo. Secondary endpoints included percent changes in triglyceride levels at 12 months, percent changes in other lipid parameters and adjudicated acute pancreatitis event rates over the treatment period. Following treatment and the end-of-trial assessments, patients were eligible to enter an open-label extension study to continue receiving olezarsen once every four weeks. About Ionis Pharmaceuticals, Inc. For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis has discovered and developed six marketed medicines for serious diseases, including breakthrough medicines for neurologic and cardiovascular diseases. Ionis has a leading pipeline in neurology, cardiology and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter) , LinkedIn and Instagram . Ionis Forward-Looking Statements This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of TRYNGOLZA, Ionis' technologies and other products in development. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including but not limited to those related to our commercial products and the medicines in our pipeline, and particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. Except as required by law, we undertake no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended Dec. 31, 2023 , and most recent Form 10-Q, which are on file with the SEC. Copies of these and other documents are available at www.Ionis.com . Ionis Pharmaceuticals® and TRYNGOLZATM are trademarks of Ionis Pharmaceuticals, Inc. Ionis Investor Contact: D. Wade Walke , Ph.D. info@ionis.com 760-603-2331 Ionis Media Contact: Hayley Soffer media@ionis.com 760-603-4679 View original content: https://www.prnewswire.com/news-releases/tryngolza-olezarsen-approved-in-us-as-first-ever-treatment-for-adults-living-with-familial-chylomicronemia-syndrome-as-an-adjunct-to-diet-302336747.html SOURCE Ionis Pharmaceuticals, Inc.WARMINSTER, Pa. , Dec. 19, 2024 /PRNewswire/ -- Havis, a trusted provider of innovative technology mounting and mobility solutions, is proud to announce its presence at the National Retail Federation (NRF) 2025 Conference & Expo, running from January 12–14, 2025, at the Jacob K. Javits Convention Center in New York City . This year, Havis is showcasing cutting-edge end-to-end solutions designed to drive efficiency, enhance customer experiences, and empower businesses to meet current and emerging challenges in retail, hospitality, warehousing, and logistics. End-to-End Solutions Built for Today's Challenges What to Expect at Booth #5965 Immersive Demonstrations Experience hands-on demonstrations of Havis solutions in real-world applications, illustrating their versatility and impact. Tailored Insights Meet with our expert team for personalized recommendations that address your unique operational challenges. Networking and Collaboration Connect with peers and industry leaders to exchange ideas and explore innovative opportunities. Havis invites NRF 2025 attendees to visit Booth #5965 and experience how its innovative technology solutions transform industries. From retail and hospitality to warehousing and logistics, Havis is redefining efficiency, security, and customer satisfaction. More Info About Havis Havis, Inc. is a privately held, ISO 9001-certified company that is the leader in providing robust and reliable end-to-end technology mounting and mobility solutions in demanding environments. The Havis legacy dates back over 80 years as a trusted designer and manufacturer of critical equipment that ensures critical technology is accessible, secure and reliable. Havis's engineering and manufacturing teams are committed to consistently researching and developing unique products and solutions for a range of industries worldwide. With headquarters in Warminster, PA , and additional locations in Plymouth, MI , Burnsville, MN , Hilliard, OH and in the UK, Havis currently employs more than 400 team members. For more information on Havis, please call 1.800.524.9900 or visit http://www.havis.com . View original content to download multimedia: https://www.prnewswire.com/news-releases/havis-to-showcase-advanced-end-to-end-solutions-for-retail-hospitality-and-logistics-at-nrf-2025-302336561.html SOURCE Havis, Inc.
Walgreens Boots Alliance, Inc. (NASDAQ:WBA) Shares Sold by MAI Capital Management
Pep Guardiola challenged "fragile" Manchester City to accept their reality and break a shocking slump that extended to a fifth straight loss as Tottenham ran amok at the Etihad Stadium. The reigning champions' hopes of an unprecedented fifth successive Premier League crown are evaporating as they continue to spiral. A run that started with last month's defeat at Tottenham in the Carabao Cup continued as Ange Postecoglou's side survived an early storm to inflict a humiliating 4-0 defeat on the shell-shocked hosts on Saturday. City's 52-match unbeaten home streak in all competitions went up in smoke as James Maddison's first-half brace was followed up by Pedro Porro and Brennan Johnson efforts after the break. "When you lose 0-4 there is nothing to say, it's congratulations Tottenham," Guardiola, whose contract extension until 2026 was announced two days before this thumping, said. "We struggled a little bit to get the balls back. We are not able to win it or the extra action afterwards but (on the ball) we were quite decent. "We created a lot, and we created a lot of chances in front of the keeper. We are a bit fragile right now, that is obvious. We struggled to score goals and after, when they arrived, they scored. "We are playing a little bit in our thoughts, a little bit of negativity but this is normal. "Football is a sense of mood and when you win a lot it gives you self-awareness you can do it and when you lose three games in a row in the Premier League that situation is there. Many things are going to happen. "We have to break the results because the victories help us to be more positive and confident and we have to do it. "But after eight years here I knew sooner or later we would drop. "I never expected to lose three Premier League games in a row, but we have been incredibly consistent again and again and again and now we cannot deny the reality that sometimes happens in football and life is here. "We have to do everything to change, especially for the next one, but the exceptionality we lived in eight years is not eternal. Sometimes you drop a little bit." Guardiola says City "cannot run away" and "have to face" the issues head on as Feyenoord arrive in the Champions League on Tuesday before next Sunday's trip to table-topping Liverpool. This is the worst run of the City boss' managerial career but he believes improvements will come as players return, although he brushed aside any title talk after this latest loss. "I would say when you lose three games in a row it is the most wrong thing to say that you will be champions," Guardiola said. "I know the guys, I know they will be back and if I'm going to doubt about them it is something wrong about me. "Maybe I will not be good enough to get back in those situations, and we will see, but I've been a football player. "What we have done in the past is exceptional but losing three Premier League games in a row can happen. It happened to me with Barcelona in LaLiga. "Now everything is a little bit against - when you feel confident the results are good, but now it is the opposite. We have to break it quick and accept it. "The best way to go through the position is accept the reality. It's not about me, you, the weather or the grass, we have to start to winning games. "Now you realise how difficult what we have done is. You can be worse but when you said to me when you win 10 or 11 or 12 or 13 games in a row you're going to win before the game, I don't know. "Now we recover and on Tuesday we have to be here again and hopefully we will change the dynamic."